Novo Nordisk's Hemophilia Filing Slips as Obesity Data and Buybacks Carry the Story
Published on 10/11/2026 at 19:10 | Editorial boerse-global.de
Novo Nordisk investors are being asked to look past a regulatory hiccup and focus on the longer arc of the company's pipeline. The US Food and Drug Administration has extended its review of Denecimig, the Danish drugmaker's candidate for hemophilia A, while fresh clinical results for semaglutide and CagriSema keep the metabolic franchise in the spotlight. Management, for its part, is holding firm on full-year guidance.
Manufacturing fix pushes Denecimig decision out
The FDA's decision to keep the Denecimig application under review stems from ongoing remediation work at a production facility, not from any deficiency in the efficacy or safety data Novo Nordisk submitted. The company was explicit on that point. No new action date has been set by the regulator.
Even so, Novo Nordisk still aims to bring the therapy to the US market in the first half of 2027, assuming approval comes through. The delay, the company stressed, does not alter its financial forecast for the full year 2026.
Liver-fat data adds another string to semaglutide's bow
Roughly two weeks ago, at the annual EASD meeting, Novo Nordisk unveiled a post-hoc analysis of a participant subgroup from the STEP UP trial — patients living with obesity rather than diabetes. Among those with elevated liver fat, semaglutide produced marked improvements at two dose levels. By week 72 of treatment, 88.5% of these patients had returned to a normal liver-fat reading below 5%.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The findings are purely clinical in nature and do not represent a regulatory label expansion. They nonetheless reinforce the breadth of semaglutide's potential across metabolic conditions.
Pipeline bets stretch beyond the core
Novo Nordisk has been busy widening its development pipeline outside its mainstay areas. Through an exclusive licensing agreement with Jiangsu Hengrui Pharmaceuticals, the group secured rights to the drug candidate HRS-1596. The deal carries a $300 million upfront payment and could be worth as much as $2.6 billion once potential milestones are included.
Separately, the company presented detailed results for its obesity candidate CagriSema, which showed a 22.4% reduction in body weight after 52 weeks, alongside a clear decrease in fat tissue in the liver, pancreas and abdomen. Such data are central to management's effort to shore up its position in future metabolic therapies.
Buyback keeps running as the stock lags
Alongside its research push, Novo Nordisk is pressing ahead with its existing capital-return program. Between February 4 and October 2, the company repurchased 36,604,179 B shares for a total of more than DKK 10.24 billion. The program's overall ceiling stands at up to DKK 15 billion.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
The shares finished Friday at EUR 34.40, up 1.3% on the day. The broader picture remains difficult, though: the stock is down 22% since the start of the year.
Citi trims its target
Cautious commentary arrived about two weeks ago from Citi Research, which lowered its price target to DKK 296 from DKK 310 while keeping a Neutral rating. The analysts pointed to limited prospects for margin growth through 2030. While the Denecimig delay does not weigh on near-term financial targets, it does highlight the demanding operational standards facing Novo Nordisk's manufacturing sites — and for investors, how quickly the company resolves those production issues, and whether its clinical research confirms further uses, will be what matters most.
Ad
Novo Nordisk Stock: New Analysis - 11 October
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
